Patient-Derived Specimen Procurement & Processing

The contract involves the collection, preservation, and initial processing of patient-derived biological specimens including bone marrow and blood from individuals diagnosed with myelodysplastic syndromes and chronic myelomonocytic leukemia, exclusively for use in gene editing research. The work requires strict adherence to clinical protocols to ensure specimen integrity, proper labeling, and timely transportation under controlled environmental conditions to support downstream genomic analysis. All procedures must comply with ethical and regulatory standards for human subject research and biospecimen handling. This subcontract is issued under the National Institutes of Health, part of the Department of Health and Human Services, with a NAICS code of 621991 indicating it pertains to other miscellaneous ambulatory health care services. The opportunity was posted on June 30, 2026, with a response deadline of July 9, 2026, at 1:00 PM. Although the place of performance and point of contact details are unspecified, the work is expected to be conducted at facilities capable of handling high-risk biological materials with appropriate certifications and infrastructure. No set-aside criteria are indicated, meaning the contract is open to all qualified entities.